NEW YORK (GenomeWeb) – Invivoscribe announced today that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved the firm's LeukoStrat CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo's quizartinib for the treatment of FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML) patients.